ASCO 2019: New promising drug for second-line SCLC patients

Lurbinectedin is a novel anticancer drug that inhibits activated transcription and induces DNA double-strand breaks, leading to apoptosis. In this MEDtalk Bjørn Henning Grønberg explain, why he think, that Lurbinectedin is a new promising drug for second-line SCLC patients.